Specialized in developing genetically engineered mouse models, GenoBioTX proudly offers an inventory of 9000 catalog mouse models and has successfully customized over 19,000 strains for clients. GenoBioTX also provide more than 600 humanized mouse models for drug discovery. Beyond this, GenoBioTX has expanded into pre-clinical CRO services across diverse disease areas, especially immuno-oncology. Our commitment to innovation and client satisfaction continues to drive our success in the dynamic field of drug discovery. For more information, go to https://www.modelorg.com/en/.

Lyophilization Technology, Inc. is a Contract Development and Manufacturing Organization. The company conducts applied research, provides comprehensive scientific services and technical support ranging from developing new freeze-dried products and processes, streamlining operations to improving compliance, and manufactures clinical supplies for freeze dried pharmaceuticals, biologics, diagnostics, biopharmaceuticals and fine chemicals. To learn more, please visit https://www.lyotechnology.com/

RareCyte provides Precision Biology™ products and services for discovery, translational research and clinical diagnostics. The Orion™ spatial biology platform enables whole-slide highly multiplexed tissue analysis for multiple samples per day. Comprehensive liquid biopsy offerings enable CTC and other rare cell characterization and single cell retrieval for molecular analysis and CDx development. For more information, go to https://rarecyte.com/

Serimmune is an immune intelligence company focused on identifying and exploiting the universe of relationships between antibodies and antigens. Our proprietary technology (SERA) provides a holistic view of the circulating antibody repertoire to identify diverse immunogenic factors in disease and health. Serimmune’s human immunity map is a growing database that can be interrogated to fuel the development of multiplex diagnostics, vaccines, and therapeutics. Serimune is in Santa Barbara, CA with strong ties to University of California Santa Barbara where the SERA technology was originally developed.

Press Ganey, the leading Human Experience (HX) healthcare performance improvement company, offers an integrated suite of solutions that address safety, clinical excellence, patient experience and workforce engagement. The company works with more than 41,000 healthcare facilities in its mission to reduce patient suffering and enhance caregiver resilience to improve the overall safety, quality and experience of care. Press Ganey is a PG Forsta company.

Nona Biosciences specialized in fully human therapeutic antibody technology. Our proprietary Harbour Mice® technology are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform is fully optimized and clinically validated with global patented protection.

MedQIA, WorldCare Clinical and DARC, have come together to form Voiant, the industry’s leading clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise. Voiant’s unique AI-based software platform integrates all aspects of clinical trial imaging, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data.

BDD has world leading expertise in the development and clinical testing of innovative pharmaceutical products. Our development strategies are underpinned by our understanding of biopharmaceutics which has evolved over years of experience in visualising in vivo performance of products using gamma scintigraphy. BDD combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. To learn more, please visit https://www.bddpharma.com/

Clinical Outcomes Solution is a global health economics and outcomes research consulting group providing 360° support and services across all facets of clinical outcomes research to assist with data-driven decisions for informing patient care. www.clinoutsolutions.com

Biond Biologics is a private, clinical-stage biotech company, developing a pioneering intracellular drug delivery platform called INspire and innovative Immuno-oncology therapies. INspire, delivers biologics, e.g., nanobodies and proteins for intracellular targets considered hard-to-target such as the RAF, RAS proteins. Our IO pipeline includes three novel biological drugs, BND-22 an anti ILT2/LILRB1 antibody, licensed to Sanofi and is in phase 1; BND-35 an anti ILT3/LILRB4, with phase 1 initiating in H1 2024 and BND-67 - A nanobody based agent targeting CD28 shedding potentially effecting resistance to anti-PD-1 therapy.

Virogin Biotech is a clinical-stage immuno-oncology company, with a primary focus on innovative HSV-1 based oncolytic virus (OV) and mRNA-based (including self-amplifying RNA/saRNA) therapeutics to elicit robust and durable anti-tumor immune response against solid tumors. Both the platforms exhibit a high degree of complementarity via a mechanism of heterologous prime-boost. Enhanced anti-tumor efficacy has been observed if OV and mRNA tumor vaccines were combined due to (1) modulation of immune-suppressive tumor microenvironment through release of immunological payloads carried by OV, and (2) antigen spread via direct tumor cell lysis triggered by OV infection, which functions like an in situ personalized tumor vaccine. Yet each platform has ‘plug-to-play' features to independently develop novel therapies against cancer & other indications. Our oncolytic HSV-1 platform has two candidates in clinical trials, with our most advanced asset in Phase 2. Candidates from our mRNA platform have also completed preclinical proof of concept.

Saros Therapeutics is a private, pre-clinical biotech company developing therapies that enhance the immune response against cancer by targeting STING. The technology was engineered to overcome problems of prior STING therapies through cell specific targeting, increased potency and a better route of administration. Successful development of Saros' lead program will bring tremendous benefits to patients with many different types of cancer.